Intracellular pH is a fundamental parameter to cell function that requires tight homeostasis. In the absence of any regulation, excessive acidi�cation of the cytosol would have the tendency to produce cellular damage. Mammalian Na + /H + exchangers (NHEs) are electroneutral Na + -dependent proteins that exchange extracellular Na + for intracellular H + . To date, there are 9 identi�ed NHE isoforms where NHE1 is the most ubiquitous member, known as the housekeeping exchanger. NHE1 seems to have a protective role in the ischemia-reperfusion in�ury and other in�ammatory diseases. In nociception, NHE1 is found in neurons along nociceptive pathways, and its pharmacological inhibition increases nociceptive behavior in acute pain models at peripheral and central levels. Electrophysiological studies also show that NHE modulates electrical activity of primary nociceptive terminals. However, its role in neuropathic pain still remains controversial. In humans, NHE1 may be responsible for in�ammatory bowel diseases since its expression is reduced in Crohn's disease and ulcerative colitis. e purpose of this work is to provide a review of the evidence about participation of NHE1 in the nociceptive processing.
Introduction
Intracellular pH (pHi) is a fundamental parameter to cell function that requires tight homeostasis [1] . In the absence of any regulation, the cytosol would have the tendency to become acidi�ed due to the continuous buildup of metabolic acid (H + ) equivalents [2, 3] . Cells have developed means to raise cytosolic pH, guarding against dangerous acidi�cation. Regulation of pHi comprises several processes such as cytosolic H + buffering, H + sequestration into cellular organelles, and transmembrane movement of acid equivalents [1, 3, 4] . Cells regulate rapid and localized pH swings by their intrinsic pH buffering capacity which is provided by several intracellular weak acids and bases. Moreover, cells regulate pH through the bicarbonate (HCO 3 − ) buffer system which combines with excess H + ions to form carbonic acid [5] . en, carbonic acid is transformed to carbon dioxide (CO 2 ) by the enzyme carbonic anhydrase [5] . e total buffer capacity includes both components [1, 2, 4] . Although effective this buffering system has limited capacity to counteract continuous generation of H + equivalents by metabolism, ongoing transport of ions that alter the pH (H + and HCO 3 − ), or the presence of diseases that contribute to extracellular acidi�cation (in�ammation, hypoxia, or ischemia). e mechanism of regulation of pHi carried out by transporters requires energy as H + is transported against its electrochemical gradient. us, transporters use the inward Na + gradient produced by the 3Na + /2K + -ATPase. Several proteins carry out this function being one of the most important Na + /H + exchangers [1, 6, 7 ].
Mammalian Na + /H + exchangers (NHEs) are electroneutral Na + -dependent proteins that exchange extracellular Na + for intracellular H + [8] [9] [10] . In animal cells, they are linked to a variety of physiological roles which include regulation of pHi and cell volume [6, [10] [11] [12] [13] . Between the different NHE isoforms identi�ed, NHE1 is the most ubiquitous member [9, 10] . In pathological conditions, the activity of NHE1 has been related to growth of some tumor cells [14] . Moreover, NHE1 has been proposed as a mediator of the myocardial damage that occurs aer ischemia-reperfusion injury [15, 16] . However, recent studies with transgenic mouse models expressing elevated NHE1 levels have demonstrated less susceptibility to ischemia-reperfusion injury [17] [18] [19] suggesting that NHE1 plays a protective instead of noxious effect in this pathology. Besides its role in cancer and ischemia, recent evidence has shown the NHE1 plays an important role as a protective mechanism in nociceptive sensory neurons. e aim of this work is to provide a review of the role of NHE1 in the nociceptive processing. induced by formalin suggesting that NHE1 plays a role as a protective system in chronic pain as well [58] . Reinforcing this, NHE1 is downregulated from day 1 to 12 aer formalin injection [58] . Similar results have been observed in biopsies from patients with ulcerative colitis and Crohn's disease that present an in�ammatory process and abdominal pain [59, 60] .
Neuropathic
Pain. e role of NHE1 in neuropathic pain has been less studied. Systemic injection of amiloride attenuated chronic constriction injury-and vincristine-induced neuropathic pain [61] . Authors attributed the observed antinociceptive effects of amiloride to the inhibition of NHE with subsequent decrease in Ca 2+ ions and oxidative stress. However, since they used doses of amiloride that also block acid sensing ion channels (ASICs) [62] , it is likely that these effects may result from the blockade of ASICs instead of NHE. However, the �nal answer still needs con�rmation.
Contrary to the results in in�ammatory pain and in the skin-nerve preparation, other authors have reported that blockade of NHE1 by zoniporide reduces the amplitude of the compound action potential recorded from the dorsal root [63] . is study showed that blockade of NHE1 may reduce peripheral neuronal excitability by shiing fast Na + channels into the inactivated state under physiological conditions. ese actions may lead to antinociceptive effects. However, the same group has reported that continuous intravenous infusion of zoniporide to rats and dogs for up to 1 month, but not for 2-weeks, produced peripheral neuropathies (axonal degeneration), in the spinal cord (dorsal funiculus), dorsal roots, and dorsal root ganglia [64] . us, more research is need on this point to clarify the role of NHE1 in neuropathic pain.
NHE in Nociceptive
Neurons. NHE1 has been reported in dorsal root ganglia, dorsal spinal cord, and trigeminal neurons. NHE1 mRNA and protein expression are observed in dorsal root ganglia and dorsal spinal cord of rats [55] . Moreover, NHE5 protein is observed in spinal cord but not in dorsal root ganglia [55] . NHE1 is mainly expressed in the lamina I of the dorsal horn of the spinal cord and it colocalizes with peptide-rich sensory nerve �ber markers, substance P, and calcitonin gene-related peptide [56] . Others have found NHE1 in trigeminal ganglia [65] and colonic mucosa [59, 66] . Furthermore, NHE1 transcript has been found in human dorsal root ganglion [67, 68] . Data about the localization of NHE1 in neurons suggest that regulation of pHi may play a role in the nociceptive processing at peripheral and central sites ( Figure 2 ).
NHE in Schwann Cells
. NHE1 has been found in primary cultures of Schwann cells from rat sciatic nerve [69] . Authors found that NHE was moderately active at steady-state pHi. More recently, NHE3 has been found in Schwann cells on the laryngeal nerve [70] . Nerve �bers and nerve cell bodies of Schwann cells and satellite cells were surrounded by both proteins. It is likely that, as in other cells, NHE plays a role in Schwann cells regulating pHi. However, it has been reported that NHE may have a role in proliferation of Schwann cells as inhibition of NHE aer addition of a mitogen signi�cantly reduced the degree of mitosis [71] .
NHE in Microglia.
NHE1 is expressed in resting microglia [72] . Pharmacological inhibition of NHE1 activity acidi�es primary or immortalized M4T.4 microglia in resting conditions and blockades pHi recovery capacity aer experimental acidi�cation [72] [73] [74] . ese data suggest that NHE1 C-terminal   CHP   XII  XI  X  IX  VIII  VII  VI  V  IV  III  II  I   N-terminal   XII  XI  X  IX  VIII  VII  VI  V  IV  III  II  I plays a key role in maintaining pHi in resting conditions and extruding H + aer acidosis in microglia. Activation of microglia by lipopolysaccharide does not change the expression of NHE1 but increases the activity to maintain pHi. In addition, lipopolysaccharide increases the production of the superoxide radical (O 2
•− ) in microglia while inhibition of NHE1 reduces microglial activation and proin�ammatory response. ese data suggest that NHE1 participates in the generation of O 2
•− through maintaining H + homeostasis, thereby allowing for sustained NADPH oxidase complex activation in activated microglia [72] . Free radicals can subse�uently lead to release of cytotoxic proin�ammatory cytokines. Since microglial activation and release of cytokines have been associated with in�ammatory and neuropathic pain [75, 76] , it has been suggested that NHE1 may be one of the mechanisms to increase microglial activity and sustain neuropathic pain [63, 64] .
NHE in Astrocytes.
Astrocytes play an important role throughout the central nervous system among others regulating pH [13] . Injury or stress to the central nervous system activates astrocytes, which then display an altered morphology and protein expression [77] . NHE1 protein has been found in astrocytes [78] [79] [80] [81] . It seems that NHE1 is moderately active in basal conditions, but it can be activated by phosphorylation through tyrosine kinase (TK), ERK 1/2 , and p90 rsk , in astrocytes [78, 82, 83] further promoting extrusion of acid. Other substances like tumor necrosis factor-alpha (TNF ), interferon-, interleukin-1 beta (IL-1 ), and hydrogen sul�de (H 2 S) also produce intracellular acidi�cation and activation of NHE in astrocytes. In contrast, cyclic GMP-inducing C-type natriuretic peptide and cyclic GMP inhibit NHE in astrocytes [84] .
2.�. �o�e o� NHE� in �n�����tory ��in in H���ns.
In�ammatory bowel diseases such as Crohn�s disease and ulcerative colitis have been associated with defects in homeostasis of cations as revealed by altered expression of several cation transporters [59, 85] . It is thought that these defects may be responsible for motility dysfunction, diarrhea, and pain commonly seen in patients with this type of diseases. NHE1 plays an important role in cation homeostasis of the gastrointestinal tract [27] . ere are consistent reports that NHE1 is reduced in ulcerative colitis and Crohn's disease in humans [59, 60] . Authors suggest that this reduced expression may compromise recovery of acidic pHi, and thus it may contribute to tissue necrosis and probably to pain [59, 66] . However, on the bases of the present data, we cannot discharge that other mechanisms might be contributing to produce the characteristic symptoms of the Crohn's disease and ulcerative colitis. On the contrary, NHE inhibition of human gut epithelial cells suppressed interleukin-8 production and activation of the p42/p44 mitogen-activated protein kinase and nuclear factor-kappaB. Furthermore, NHE inhibition ameliorated the course of in�ammatory bowel disease in dextran sulfatetreated mice [86] . In support of this, NHE inhibitors may produce an anti-in�ammatory effect by inhibiting the production of PGE 2 and the increase in COX-2 protein levels [87] . Differences could be due to the experimental approach used. However, more studies are needed in order to clarify this issue.
Perspectives and Conclusion
. e role of NHE1 in nociception has recently been discovered. Data suggests that NHE1 plays a protective role in acute and chronic in�am-matory pain. However, the role of NHE1 in neuropathic pain is controversial. Since NHE1 inhibitors produce an increase of in�ammatory pain, the study of NHE1 inhibitors in neuropathic pain is difficult because models of neuropathic pain do not allow getting a graded level of allodynia in such way that blockade of NHE1 would allow assessing an increase in tactile allodynia. e development of NHE1 activators could help to solve the problem. e results observed in the acute and chronic model of in�ammatory pain induced by formalin should be corroborated in other models of in�ammatory pain. Particularly, the use of models related to chronic in�ammatory conditions, in which acidi�cation is a common feature, such as the injection of complete Freund's adjuvant (CFA), monoiodoacetate (MIA), or uric acid, is recommended. e use of knock-out mice as well as interference RNA directed against NHE1 and other members of the family would be helpful to delineate the participation of these proteins in the modulation of pain. e wide distribution of NHE1 could represent a challenge for drug development. Besides nociceptive neurons, NHE1 is found in heart and brain. us, activation of NHE1 may lead to side effects in those sites. However, the integrated study of the pHi regulation involving NHE1 will de�nitely produce the basis to understand how nociceptive sensory neurons function in presence of the acidic conditions. 
